FDA Expands Pluvicto Into PSMA-Positive Hormone-Sensitive Prostate Cancer

Company: Novartis · Event Type: Regulatory Approval – Indication Expansion · Product: Pluvicto (lutetium Lu 177 vipivotide tetraxetan) · Indication: PSMA-Positive Metastatic Hormone-Sensitive Prostate Cancer · Approval Date: July 31, 2026 Summary The FDA has approved Pluvicto (lutetium Lu 177 vipivotide tetraxetan), used in combination…